Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling

Papillary thyroid carcinoma (PTC) is a miscellaneous disease with a variety of histological variants, each with its own mutational profile, and clinical and prognostic characteristics. Identification of microRNA (miRNA) expression profiles represents an important benchmark for understanding the molecular mechanisms underlying the biological behavior of these unique PTC subtypes in order that they be better characterized. We considered a series of 35 PTC samples with a histological diagnosis of either hobnail (17 cases) or classical variant (nine cases) and with a specific BRAF p.K601E mutation (nine cases). We determined the overall miRNA expression profile with NanoString technology, and both quantitative reverse transcription–PCR and in situ hybridization were used to confirm selected miRNAs. The miRNA signature was found to consistently differentiate specific histotypes and mutational profiles. In contrast to the BRAF p.K601E mutation and classic PTCs, three miRNAs (miR-21-5p, miR-146b-5p, and miR-205-5p) were substantially overexpressed in the hobnail variant. The current study found that different miRNA signature profiles were linked to unique histological variants and BRAF mutations in PTC. Further studies focusing on the downstream pathogenetic functions of mRNAs in thyroid neoplasms are warranted.

[1]  E. Kimura,et al.  Targeting the Highly Expressed microRNA miR-146b with CRISPR/Cas9n Gene Editing System in Thyroid Cancer , 2021, International journal of molecular sciences.

[2]  Yan Liu,et al.  A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroid carcinoma , 2021, PloS one.

[3]  M. Fassan,et al.  MicroRNAs in Medullary Thyroid Carcinoma: A State of the Art Review of the Regulatory Mechanisms and Future Perspectives , 2021, Cells.

[4]  N. Chauhan,et al.  miR-205: A Potential Biomedicine for Cancer Therapy , 2020, Cells.

[5]  M. Sorokin,et al.  Reciprocal Dysregulation of MiR-146b and MiR-451 Contributes in Malignant Phenotype of Follicular Thyroid Tumor , 2020, International journal of molecular sciences.

[6]  Wenqian Jiang,et al.  Downregulation of miR-146b-5p via iodine involvement repressed papillary thyroid carcinoma cell proliferation. , 2020, Journal of molecular endocrinology.

[7]  Jian Sun,et al.  miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma , 2019, Human Cell.

[8]  Hong-Yo Kang,et al.  MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer , 2017, International journal of molecular sciences.

[9]  A. Sapino,et al.  Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma. , 2017, Endocrine-related cancer.

[10]  S. Benvenga,et al.  The micropapillary/hobnail variant of papillary thyroid carcinoma: A review of series described in the literature compared to a series from one southern Italy pathology institution , 2016, Reviews in Endocrine and Metabolic Disorders.

[11]  M. Rugge,et al.  MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma , 2016, British Journal of Cancer.

[12]  M. Rugge,et al.  BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience , 2016, Clinical chemistry and laboratory medicine.

[13]  A. Tischler,et al.  Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. , 2016, JAMA oncology.

[14]  Simion I. Chiosea,et al.  Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation. , 2016, Thyroid : official journal of the American Thyroid Association.

[15]  A. Salajegheh,et al.  Modulatory role of miR-205 in angiogenesis and progression of thyroid cancer. , 2015, Journal of molecular endocrinology.

[16]  Alan Sharpe,et al.  High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma. , 2015, Cancer research.

[17]  Robert A. Smith,et al.  The important roles of miR-205 in normal physiology, cancers and as a potential therapeutic target. , 2014, Current cancer drug targets.

[18]  D. Dias-Santagata,et al.  Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. , 2014, Thyroid : official journal of the American Thyroid Association.

[19]  Julia B. Cordero,et al.  MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer , 2014, Cancer cell.

[20]  C. Croce,et al.  Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer , 2013, PloS one.

[21]  M. Nikiforova,et al.  MicroRNA Signature Distinguishes the Degree of Aggressiveness of Papillary Thyroid Carcinoma , 2011, Annals of Surgical Oncology.

[22]  Kuender D Yang,et al.  miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. , 2010, Thyroid : official journal of the American Thyroid Association.

[23]  R. Lloyd,et al.  Papillary Thyroid Carcinoma With Prominent Hobnail Features: A New Aggressive Variant of Moderately Differentiated Papillary Carcinoma. A Clinicopathologic, Immunohistochemical, and Molecular Study of Eight Cases , 2010, The American journal of surgical pathology.

[24]  Shuji Fujita,et al.  Locked Nucleic Acid In situ Hybridization Analysis of miR-21 Expression during Colorectal Cancer Development , 2009, Clinical Cancer Research.

[25]  C. Nucera,et al.  Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). , 2009, Biochimica et biophysica acta.

[26]  S. Schokrpur,et al.  Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.

[27]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[28]  G. Tseng,et al.  MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. , 2008, The Journal of clinical endocrinology and metabolism.

[29]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[30]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  V. Trovisco,et al.  Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness , 2005, Virchows Archiv.

[32]  M. Gariboldi,et al.  Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer , 2004, Oncogene.

[33]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[34]  C. Brown,et al.  Primary malignant tumours of the thyroid: The relationship between histological classification and clinical behaviour , 1976, The British journal of surgery.

[35]  J. Mejzlík,et al.  MicroRNA Deregulation in Papillary Thyroid Cancer and its Relationship With BRAF V600E Mutation , 2021, In Vivo.

[36]  S. Barollo,et al.  The Hobnail Variant of Papillary Thyroid Carcinoma: Clinical/Molecular Characteristics of a Large Monocentric Series and Comparison with Conventional Histotypes. , 2018, Thyroid : official journal of the American Thyroid Association.

[37]  M. Rugge,et al.  PDCD4 expression in thyroid neoplasia , 2012, Virchows Archiv.

[38]  S. Pilotti,et al.  Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma , 2002, Virchows Archiv.

[39]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .